Ipswich Investment Management Co. Inc. Has $515,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Ipswich Investment Management Co. Inc. reduced its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 4.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 6,959 shares of the medical research company’s stock after selling 300 shares during the period. Ipswich Investment Management Co. Inc.’s holdings in Edwards Lifesciences were worth $515,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in EW. Abacus Planning Group Inc. boosted its holdings in shares of Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after buying an additional 140 shares during the period. Bowman & Co S.C. lifted its position in shares of Edwards Lifesciences by 1.2% in the fourth quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company’s stock worth $924,000 after purchasing an additional 148 shares in the last quarter. Pegasus Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 0.4% in the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company’s stock worth $3,156,000 after purchasing an additional 159 shares in the last quarter. Mount Yale Investment Advisors LLC lifted its position in shares of Edwards Lifesciences by 1.9% in the fourth quarter. Mount Yale Investment Advisors LLC now owns 8,563 shares of the medical research company’s stock worth $634,000 after purchasing an additional 162 shares in the last quarter. Finally, JFS Wealth Advisors LLC lifted its position in shares of Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after purchasing an additional 166 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 2.0 %

EW stock opened at $73.25 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company’s 50-day simple moving average is $72.85 and its 200 day simple moving average is $69.94. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $43.20 billion, a PE ratio of 10.51, a price-to-earnings-growth ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on EW shares. Robert W. Baird cut their price objective on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group boosted their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. Morgan Stanley boosted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.